MTOR and ovarian carcinoma: Recent studies have also demonstrated that METTL3-mediated m6A modification can activate the PI3K/AKT/mammalian target of rapamycin (mTOR) pathway in ovarian cancer (OC) (117) and retinoblastoma (Rb) (118).